前列腺液-尿液混合物中前列腺癌生物标志物的研究现状

Research status of biomarkers in expressed prostatic secretion-urine for prostate cancer

随着我国逐渐进入老龄化社会,前列腺癌已成为老年男性人群中最常见的生殖系统肿瘤。前列腺穿刺是目前诊断前列腺癌的金标准,但因其阳性率低及术后并发症较多,患者在就诊时往往选择拒绝。同时,前列腺癌还具有高度的异质性,对患者进行预后风险分组仍是一大挑战。因此,探寻用于诊断和判断预后的生物标志物具有重要的临床意义。通过对前列腺液-尿液混合物进行深入的研究后,越来越多的蛋白质种类和代谢产物得以被发现,同时以此作为生物标志物建立的预测模型也不断被提出。本文就前列腺液-尿液混合物中的前列腺癌生物标志物的研究现状进行综述。

As our country has gradually entered the aging society,prostate cancer has become the most common tumor of the reproductive system in the elderly male population.Prostate biopsy is currently the gold standard for the diagnosis of prostate cancer,but patients often choose to refuse at presentation because of its low positive rate and more postoperative complications.At the same time,prostate cancer is also highly heterogeneous,and the prognostic risk grouping of patients is still a major challenge.Therefore,it is of great clinical significance to explore biomarkers for diagnosis and prognosis.After intensive study of expressed prostatic secretion(EPS)-urine,more and more kinds of protein species and metabolites have been discovered,and predictive models built as biomarkers have been proposed.This article reviews the research status of biomarkers in EPS-urine for prostate cancer.